抗心律失常新药Pirmenol首次试用于临床,证明具安全有效特点。该药作用机理类似局麻型抗心律失常药,动物模型试验可降低心脏Purkinje纤维0期除极及4期自动除极上升支速度。加速早期复极化,延长动作电位时间,延缓房室传导,使QRS波持续时间及QT间期明显增加,这种效应特征性地不受钾水平变化的影响。 Anti-arrhythmic drug Pirmenol for the first time in clinical trials to prove safe and effective features. The mechanism of action of the drug is similar to local anesthetic anti-arrhythmic drugs, animal model test can reduce the Purkinje fiber 0 depolarization and 4 automatic depolarization ascending velocity. Accelerate early repolarization, prolong the action potential time, delay atrioventricular conduction, the QRS wave duration and QT interval significantly increased, this effect is not affected by changes in potassium characteristics.